Introducing ADI’s new CEO: Dr. Faith Mwangi-Powell
ADI announces our new CEO, joining on 1 October 2026
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
Living Between Scans: Uncertainty, Hope and Life After a Dementia Diagnosis
In this guest article, ADI Board Member and dementia advocate, Bill Yeates, shares his post diagnosis journey, discussing the hopes and challenges of life between scans.
UK medicines regulator, MHRA approves lecanemab
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
ADI at AAIC 2024
ADI’s Diego Aguilar and Nick House attend the Alzheimer's Association International Conference in Philadelphia (USA), delivering key insights, conducting vital meetings and advocating for care in the era of new treatments.
Lancet Commission identifies two new risk factors for dementia and suggests 45% of cases could be delayed or reduced
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
EMA’s advisory committee (CHMP) recommends not granting marketing authorization for lecanemab
Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Donanemab update: new Alzheimer’s disease treatment approved by the FDA
On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease. Donanemab is the…
ADI Regional Director supporting a National Dementia Plan for Argentina
Regional Director for the Americas, Diego Aguilar, alongside politician and neuroscientist Facundo Manes, and ADI’s Argentinian member association A.L.M.A, joined for urgent action on dementia following steeply increasing dementia forecasts and stalling progress towards a National Dementia Plan in the country.
Asia Pacific Update: ADI director for the region attends international summits
In recent events, ADI Regional Director for Asia-Pacific, DY Suharya, was invited to contribute to key summits, events and meetings, with a key focus on improving dementia care, innovating dementia technology and advising on advocacy across the Asia-Pacific region and beyond.
ADI in Europe: ADI represented at vital events in Sarajevo, Stockholm, and Ljubljana
ADI is sharing a round-up of our recent action in Europe, on advocacy and research, with ADI Board Vice Chair, Meera Pattabiraman, and ADI Director of Research and Publications, Wendy Weidner. Both taking part in vital dialogues in June 2024.